Twist Bioscience Corporation $TWST Shares Sold by First Light Asset Management LLC

First Light Asset Management LLC decreased its stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 17.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 727,933 shares of the company's stock after selling 150,915 shares during the period. Twist Bioscience comprises about 4.6% of First Light Asset Management LLC's holdings, making the stock its 6th largest holding. First Light Asset Management LLC owned about 1.16% of Twist Bioscience worth $74,890,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its holdings in shares of Twist Bioscience by 10,945.7% during the second quarter. California State Teachers Retirement System now owns 7,770,424 shares of the company's stock worth $799,421,000 after buying an additional 7,700,076 shares in the last quarter. BlackRock Inc. bought a new position in shares of Twist Bioscience in the 2nd quarter valued at $600,191,000. William Blair Investment Management LLC acquired a new stake in shares of Twist Bioscience during the 2nd quarter valued at $223,722,000. EdgePoint Investment Group Inc. boosted its holdings in shares of Twist Bioscience by 31.7% during the 4th quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company's stock valued at $170,590,000 after acquiring an additional 1,295,672 shares in the last quarter. Finally, Millennium Management LLC grew its position in Twist Bioscience by 151.5% during the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company's stock worth $50,479,000 after acquiring an additional 1,080,722 shares during the last quarter.

Insider Buying and Selling

In other Twist Bioscience news, insider Dennis Cho sold 14,205 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the completion of the sale, the insider owned 105,141 shares of the company's stock, valued at approximately $9,436,404.75. This represents a 11.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Emily M. Leproust sold 41,570 shares of the firm's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $151.98, for a total transaction of $6,317,808.60. Following the transaction, the chief executive officer owned 770,729 shares of the company's stock, valued at approximately $117,135,393.42. The trade was a 5.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 192,697 shares of company stock valued at $23,998,505. Insiders own 3.08% of the company's stock.

Wall Street Analysts Forecast Growth

TWST has been the subject of several research reports. TD Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Guggenheim restated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 24th. Canaccord Genuity Group upped their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research note on Wednesday, June 24th. Finally, Barclays lifted their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 24th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $98.45.

Twist Bioscience Stock Down 2.0%

Shares of TWST opened at $125.52 on Thursday. The company has a market capitalization of $7.87 billion, a PE ratio of -56.54 and a beta of 2.22. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $155.44. The stock's 50-day moving average price is $112.40 and its two-hundred day moving average price is $78.44. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same quarter last year, the firm posted $0.33 EPS. The company's quarterly revenue was up 23.2% on a year-over-year basis. On average, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.